Theradex (Europe) Limited
Registered name: THERADEX (EUROPE) LIMITED
Theradex (Europe) Limited made £15.2m revenue and £3.1m profit in the year to 30 Jun 2025.
Theradex (Europe) Limited’s revenue grew 25% to £15.2m in the year to 30 Jun 2025, with £3.1m profit and 43 employees. The company is classified under “research and experimental development on biotechnology” and is based in Redhill; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Redhill, South East
- Age
- 34 yrs · since 1992
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 30 Jun 2022 | 30 Jun 2023 | 30 Jun 2024 | 30 Jun 2025 |
|---|---|---|---|---|
| Disclosure | No P&L | Full P&L | Full P&L | Full P&L |
| Profit & loss | ||||
| Revenue (turnover) | — | £10.8m | £12.1m | £15.2m |
| Cost of sales | — | £5.7m | £6.7m | £7.8m |
| Gross profit | — | £5.2m | £5.4m | £7.3m |
| Operating profit | — | £1.4m | £1.9m | £4.5m |
| Profit before tax | — | £1.4m | £2m | £4.6m |
| Profit after tax | — | £1.1m | £1.9m | £3.1m |
| Profit (best available) | — | £1.1m | £1.9m | £3.1m |
| Staff costs | — | £6m | £7.1m | £7.1m |
| Employees (average) | 43 | 42 | 38 | 43 |
| Ratios | ||||
| Profit margin | — | 10.1% | 15.3% | 20.3% |
| Gross margin | — | 47.8% | 44.7% | 48.4% |
| Revenue per employee | — | £258k | £320k | £353k |
| Profit per employee | — | £26.1k | £48.8k | £71.6k |
| Cash conversion | — | −249.1% | −181.1% | −41.8% |
| Growth (year on year) | ||||
| Revenue growth | — | — | ▲12% | ▲24.9% |
| Profit growth | — | — | ▲69.4% | ▲65.9% |
| Headcount growth | — | ▼2.3% | ▼9.5% | ▲13.2% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £5.2m | £8.6m | £11.7m | £3.6m |
| Net assets | £6.7m | £7.8m | £9.7m | £14.4m |
| Fixed assets | £71.9k | £50.6k | £30.2k | £37.5k |
| Current assets | £8.8m | £11.2m | £14.9m | £17.2m |
| Debtors | £2.8m | £2.3m | £2.1m | £1.8m |
| Deferred income | — | £1.8m | £3.3m | £847k |
| Cash from operations | — | −£3.4m | −£3.5m | −£1.9m |
| Source | FullAccounts · bulk data Mar 2024 | FullAccounts · bulk data Mar 2024 | FullAccounts · bulk data Mar 2025 | FullAccounts · bulk data Mar 2026 |
How the business works
- Profit margin
- 20.3%
- Profit ÷ revenue.
- Gross margin
- 48.4%
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £353k
- Revenue ÷ average employees.
- Profit per employee
- £71.6k
- Profit ÷ average employees.
- Cash conversion
- −41.8%
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- 0.3%
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- 5.6%
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- 11.9%
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▲48%
- Now £14.4m
- Cash at bank
- ▼69%
- Now £3.6m
- Headcount
- ▲13%
- Now 43
- Deferred income
- ▼74%
- Now £847k
- Fixed assets
- ▲24%
- Now £37.5k
Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.
Similar profitable businesses
- Enara Bio LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £17.4m
- Profit
- £1.3m
- Staff
- 54
- Dna Legal LimitedFrome · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £3.2m
- Staff
- 55
- Askbio UK LtdMidlothian · Research and experimental development on biotechnology
- Revenue
- £12.5m
- Profit
- £1.8m
- Staff
- 54
- Origio LimitedFareham · Research and experimental development on biotechnology
- Revenue
- £20.1m
- Profit
- £499k
- Staff
- 82
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Biopharma Process Systems LimitedWinchester · Research and experimental development on biotechnology
- Revenue
- £10.1m
- Profit
- £142k
- Staff
- 66
Sources
Latest figures from FullAccounts for the year to 30 Jun 2025 (profit £3.1m), from the Companies House accounts bulk data published Mar 2026. Spotted an error? Request a correction.
Updated from Companies House on 23 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.